Quantcast
Last updated on April 16, 2014 at 5:31 EDT

Latest Curemark LLC Stories

2014-03-06 16:26:42

RYE, N.Y., March 6, 2014 /PRNewswire/ -- Joan Fallon, founder and CEO of Curemark LLC, a research-driven biotechnology company focused on neurological disorders, will be a featured speaker at the SXSW Interactive Festival to be held March 7-11 in Austin, Texas. SXSW Interactive, part of South by Southwest,(TM) brings together the brightest minds in cutting-edge technologies, digital creativity and startup innovation. Dr. Fallon will be joined by Amy Millman, President of...

2014-02-03 08:28:34

RYE, N.Y., Feb. 3, 2014 /PRNewswire/ -- Curemark, a drug research and development company focused on neurological disorders, announced that the company has been awarded 6 new patents for its enzyme delivery system. The new patents, issued in Europe, Australia and Central America, extend to 2030 and can be utilized for multiple enzyme products including CM-AT, Curemark's proprietary autism drug. "We are thrilled to receive these patents," stated Dr. Joan Fallon, Curemark founder and...

2013-11-04 08:27:28

RYE, N.Y., Nov. 4, 2013 /PRNewswire/ -- Curemark LLC announced that it has begun the rolling submission of a New Drug Application (NDA) for CM-AT, the company's autism treatment, with the U.S. Food and Drug Administration. CM-AT had previously been granted Fast Track status by the FDA, a designation given to drug candidates that treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. The rolling submission process allows companies...

2013-10-08 08:30:09

RYE, N.Y., Oct. 8, 2013 /PRNewswire/ -- Curemark LLC announced today the closing of $18.5 million in common equity financing led by a leading European institutional investor. Curemark will use the funds for the completion and filing requirements for its New Drug Application (NDA) for CM-AT, the company's autism treatment, and the development of the other therapies in its pipeline. "The completion of our latest financing allows us to determine the commercial pathway for CM-AT to...

2013-09-16 08:30:09

RYE, N.Y., Sept. 16, 2013 /PRNewswire/ -- Curemark LLC announced that CEO Dr. Joan Fallon will deliver the keynote at BioForward's BioScience Vision Summit in Madison, WI on September 18. Life science entrepreneurs from across the country will attend the event, which focuses on biotechnology partnerships and innovation. Dr. Fallon's address, "Growth by Association: Winning through Public and Private Partnerships," will highlight the clear benefits of the collaboration of government...

2013-08-26 08:28:44

RYE, N.Y., Aug. 26, 2013 /PRNewswire/ -- Curemark, a drug research and development company focused on neurological disorders, announced today that it has entered into a collaborative research agreement with the VTT/MSI Molecular Sciences Institute (MSI) in Berkeley, CA. Founded in 1996 by Nobel-prize winner Sydney Brenner, MSI is an independent, not-for-profit research institute. In 2011, MSI created a partnership in bioengineering with VTT (Technical Research Centre of Finland)...

2013-08-09 08:25:33

RYE, N.Y., Aug. 9, 2013 /PRNewswire/ -- Curemark, a drug research and development company focused on neurological disorders, announced that the company has been awarded a new patent for its proprietary technology CM-1212 for the treatment of individuals with drug and alcohol addiction. The new patent, #8,486,390, is entitled "Pharmaceutical Preparation for the Treatment of the Symptoms of Addiction and Methods of Diagnosing the Same." It is the third in a series of patent grants for...

2013-06-26 08:32:00

RYE, N.Y., June 26, 2013 /PRNewswire/ -- Curemark LLC CEO Dr. Joan Fallon addressed a conference of senior Obama administration officials at the White House last week on the need for government support of early-stage life sciences companies. Speaking to representatives of the White House Office of Technology and Science, the Department of Health and Human Services and the Food and Drug Administration, Dr. Fallon highlighted the benefits of government partnership with entrepreneurs...

2013-04-23 12:32:12

RYE, N.Y., April 23, 2013 /PRNewswire/ -- Curemark LLC announced a successful pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration ("FDA") regarding its CM-AT treatment for Autism. The meeting was held to discuss Curemark's Phase 3 trial results and the pathway for filing an NDA. In view of the positive guidance at this meeting, Curemark will begin filing its NDA. The FDA previously granted Curemark's CM-AT its FAST TRACK designation. "We continue to work...

2012-11-27 12:28:59

RYE, N.Y., Nov. 27, 2012 /PRNewswire/ -- Curemark announced today that it has been granted patent #8,318,158 for its proprietary technology CM-1212 for the treatment of individuals with drug and alcohol addiction. This is the second in a series of patent grants for this indication. The newest patent is entitled "Pharmaceutical Preparation for the Treatment of the Symptoms of Addiction and Methods of Diagnosing the Same." "Individuals with drug and alcohol addiction have impairments in...